Eyal Rubin - Sep 7, 2022 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
Sr. VP and CFO
Signature
/s/ Eyal Rubin
Stock symbol
PLX
Transactions as of
Sep 7, 2022
Transactions value $
$0
Form type
4
Date filed
9/9/2022, 05:03 PM
Previous filing
Feb 28, 2022
Next filing
Aug 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLX Stock Options (Right to Buy) Award $0 +350K $0.00 350K Sep 7, 2022 Common Stock 350K $1.03 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
F2 Does not include options to purchase 80,000 shares of common stock at an exercise price equal to $2.00 per share that expire on September 22, 2029.